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H
igh-throughput screening (HTS) is an important tool for
identifying molecules that modulate enzymatic activities
andisparticularlyimportantinthedevelopmentofreagentsused
in biological research and the generation of hit compounds that
initiate drug development programs.
1 Most HTS strategies rely
onﬂuorescentreporterassaysbecausetheselabelscanbedetected
rapidly and with great sensitivity, and a variety of reagents are
available that allow the ﬂuorescent properties of the assay to be
optimized.
2 Yet, it is well recognized that the labels can perturb
enzyme activities, leading to a greater number of false positive
signals,
3andthedevelopmentofarobustassaycanrequiremonths
ofeﬀort.Label-freestrategies,includingthosebasedonrefractive
index properties
4 and mass spectrometry (MS),
5 have attracted
wide interest since they can be applied to a broader range of
assays using a common format, and they can be more rapidly
developedandmorerobustsincetheyeliminatethestepsthatare
associated with installing and observing the label.
MSmethodsareparticularlyattractivebecausetheyreportthe
mass of the molecule and therefore provide speciﬁc information
ontheanalyte.Unlikemanylabel-dependentformats,MSmethods
can observe each of the species present in a reaction, including
the substrate for an enzyme, the intended products and unin-
tended components, and therefore provide a more complete
assessment of activity. Yet, MS methods have the drawback that
they often require tedious protocols for sample preparation that
decrease the throughput of the assay and signiﬁcantly increase
the cost. Methods that simplify sample preparation while main-
taining a high-throughput capacity would address this need. We
previously reporteda MS technique that combines self-assembled
monolayers (SAMs) of alkanethiolates on gold with matrix
assistedlaserdesorption/ionization(MALDI)time-of-ﬂight(TOF)
MS, a technique termed SAMDI, for assays of enzyme activities.
6
The substrates are immobilized onto SAMs in an array format
either before or after treatment with an enzyme, and the surfaces
are simply rinsed to remove salts and other components in the
reactions, treated with matrix, and analyzed with a commercial
MALDI-TOF instrument. Upon irradiation with the laser, the
monolayers are eﬃciently desorbed from the surface through
cleavage of the thiolate-gold bond and ionized, but undergolittle
fragmentation, to give relatively simple spectra that reﬂect
the masses of the alkanethiolates and corresponding disulﬁdes
(Figure 1).
6 The SAMDI method has been applied to assays of
kinases, proteases, glycosyltransferases, methyltransferases,
7
lysine deacetylases,
8 and nucleic acid ligases.
9 An early report also
described the use of SAMDI to screen 10000 small molecules to
identifyinhibitorsoftheanthraxlethalfactor.
10Inthatreport,the
screen used glass slides having an array of 10 by 10 circular
grooves, each 2 mm in diameter. Each step in the screen was
performed manually and several weeks were required to perform
and analyze all the reactions.
In this paper, we describe the translation of SAMDI to a high-
throughput format that can screen a 100000 compound library
in 24 h. This enormous increase in throughput follows from the
fabrication anduse of high-density SAMDI arrays and laboratory
automationequipmenttoperformandanalyzethereactions.The
mass spectrometry is performed on stainless steel ‘array plates’
that are modiﬁed with gold circles that are each 2.8 mm in
diameterandarearrangedinthestandardgeometryofa384-well
microtiter plate. We prepare the array plates by sequentially
washing the stainless steel substrates in individual baths of
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ABSTRACT: High-throughput screening is a common strategy used
toidentifycompoundsthatmodulatebiochemicalactivities,butmany
approachesdependoncumbersomeﬂuorescentreportersorantibodies
andoftenproducefalse-positivehits.Thedevelopmentof“label-free”
assays addresses many of these limitations, but current approaches
still lack the throughput needed for applications in drug discovery.
This paper describes a high-throughput, label-free assay that com-
bines self-assembled monolayers with mass spectrometry, in a
technique called SAMDI, as a tool for screening libraries of 100000
compounds in one day. This method is fast, has high discrimination, and is amenable to a broad range of chemical and biological
applications.
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hexanes, ethanol, water, ethanol again, and then drying with
nitrogengas.Anelectronbeamevaporatoristhenusedtodeposit
a 10 nm layer of titanium on the entire plate, which will form a
thin oxide layer as it is exposed to air during the 20 min that the
evaporator is vented to ambient pressure. The plate is then
coveredwithamaskandagainplacedintheevaporatortodeposit
titanium (4 nm) and then gold (22 nm) to create the array of
gold features. The plates are then immersed in an ethanolic
solution of terminally substituted disulﬁde reagents to assemble
maleimide-terminated monolayers on each of the gold circles, as
previously reported.
11 Finally, the plates are treated with hexa-
decyl phosphonic acid which reacts speciﬁcally with the titanium
oxide surface surrounding the gold circles.
12,13 This treatment
provides a hydrophobic surface that prevents the spreading of
aqueous solutions from the monolayers, thereby reducing the
potential for cross-contamination of the reactions.
We illustrate this approach with a screen of 100000 com-
pounds to identify inhibitors of lysine deacetylase 8 (KDAC8).
KDACs(formerlyhistonedeacetylasesorHDACs)removeacetyl
moieties from the N
ε-amino group of lysine residues and play a
role in regulating gene expression, diabetes, and cancer and
therefore have become popular therapeutic targets.
14 We also
compare the SAMDI method to a common ﬂuorescent format
that uses the commercially available Fluor de Lys (FdL) KDAC
assay.
15
Inpreparationforscreening,weorganizedacompoundlibrary
(ChembridgeDiverset)intopoolsofeightmolecules(inDMSO)
in 384-well plates. For all liquid transfers, we used a Tecan EVO
liquidhandlerwitha96-tiphead.Atotalof320wellsineachplate
hadcompoundpoolswhiletheremainingwells(theﬁrsttwoand
lasttwocolumns)wereusedforcontrols.Fortyplates,eachcom-
prising2560compounds,wereusedtoorganizeatotalof102400
compounds. Reactions were performed in 384-well plates by
adding 16 μLo fb u ﬀer (25 mM Tris-HCl (pH 8.0), 137 mM
NaCl, 2.7 mM KCl, 1.0 mM MgCl2) containing enzyme (1 μM
KDAC8 ﬁnal concentration) to each well. Next, the pooled
compounds were transferred to the reaction plates and mixed
(2μL,togiveaﬁnalconcentrationof1.25μMforeachmolecule).
The reactions were initiated by adding the KDAC8 peptide
substrateAc-GRK
AcFGC-NH2
8(2μLtogiveaﬁnalconcentration
of 10 μM), and the plate was incubated at 37 C for 60 min.
The reaction mixtures (4.5 μL each) were then transferred
ontothearrayplates(Figure2a)andkeptatroomtemperaturein
a humidiﬁed chamber for 1 h to allow the substrate/product
peptidestoimmobilizetothemaleimide-terminatedmonolayers.
We veriﬁed that both the acetylated and deacetylated forms of
thepeptideunderwentimmobilizationatacomparablerate(data
not shown). The array plates were then rinsed with deionized
ultraﬁltered water, ethanol, dried with nitrogen, and treated with
matrix (trihydroxyacetophenone, 50 mg mL
 1 inacetone).Each
plate was analyzed with an Applied Biosystems 4800 MALDI
TOF/TOF spectrometer using an automated protocol (20 kV
accelerating voltage, positive reﬂector mode, 200 laser shots per
spot), a process that requires approximately 4 s per spot. As
shown in Figure 1, representative spectra from before and after
enzyme treatment reveal two distinct peaks. The observed peak
at m/z 1601.3 corresponds to an alkyldisulﬁde of the acetylated
peptideconjugatedtothemaleimide-terminatedmonolayer,and
the peak at m/z 1559.3 corresponds to the deacetylated form of
this peptide-conjugated disulﬁde. The data (representative spec-
tra shown in Figure 2b) were analyzed in an automated fashion
using the Applied Biosystems Data Explorer Software to retrieve
the area under curves (AUCs) that correspond to the deacety-
lated peptide and starting substrate. A parameter represent-
ing the extent of reaction was calculated using the relation
AUCProduct/[AUCSubstrate þAUCProduct]foreachofthespectra.
We found that 41 of the pools displayed a greater than 30% level
of inhibition relative to control reactions that had no inhibitor
present (Supporting Information Figure 1a). We then evaluated
eachofthe328individualcompoundsandfoundthat48ofthem
showed greater than 50% inhibition (Supporting Information
Figure 1b), and we identiﬁed one compound which gave nearly
completeinhibitionandhadanIC50valueof200nM(Figure2c).
We are currently working to further characterize the activity and
Figure 1. Schematic illustration of the SAMDI assay. Maleimide-terminated self-assembled monolayers are used to covalently capture the peptide
substrates and products through reaction with the cysteine thiol group. Laser irradiation ofthe monolayer results in cleavage of the thiolate gold bond
andeﬃcientdesorptionandionizationofthechains,either asdisulﬁdesoralkanethiolates.Thestartingpeptidesubstrateusedinthescreengives riseto
the peak at a mass to charge ratio (m/z) of 1601.3, and the deacetylated products are shifted by m/z 42 to a peak at m/z 1559.3.349 dx.doi.org/10.1021/co2000373 |ACS Comb. Sci. 2011, 13, 347–350
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selectivity of this compound and corresponding derivatives with
other KDAC isoforms and in cell culture.
Intotal,thescreenwascompletedin24h.Individually,ittook
6htoprepareandimmobilizethereactionstothearrayplates,18h
to acquire 15360 individual SAMDI spectra (∼4 s/spot), and
30 min to process and evaluate the data, although many steps
were performed concurrently. The secondary screen to decon-
volute the mixtures was then completed in 3.5 h.
We also used the Fluor de Lys (FdL) assay kit (Enzo Life Sci.
Inc.) to analyze 4500 randomly selected compounds from the
same library,whichisasuﬃcientnumber ofcompoundstoallow
acomparison ofthetwoscreeningassays(Figure 3a).Theassays
wereperformedaccordingtothemanufacturer’sprotocolina96-
well assay plate using KDAC8 at a concentration of 1 μM. The
pooled compounds, at a ﬁnal concentration of 1.25 μM, were
added to each well, and control wells included the known pan-
KDAC inhibitor Trichostatin A (TSA). We identiﬁed twelve
pools(96compounds,∼2%ofthetotal)thatshowedmorethan
30% inhibition of KDAC8 activity (Supporting Information
Figure 2a). We then used the FdL assay to evaluate the 96
individual compounds from these pools and identiﬁed seven
compounds that inhibited KDAC8 activity by greater than 50%
(Supporting Information Figure 2b). The ﬁnal hit rate (deﬁned
as the percentage of compounds showing inhibition greater than
50% relative to the total number of compounds) was 0.16% for
the FdL assay, whereas with SAMDI, we obtained a hit rate of
0.05%. Interestingly, when we evaluated the seven potent hit
compoundsidentiﬁedintheFdLassaywiththeSAMDIassay,we
found that only one showed inhibition, suggesting that the
remaining six compounds are false-positive hits. This result is
consistent with a recent observation that ﬂuorescently labeled
substrates can lead to false-positive hits in screens (e.g., resver-
atrol with the deacetylase SIRT1
3). Additionally, we and others
have shown that some of the ﬂuorescently labeled KDAC
substrates are not active substrates when the ﬂuorophore is
absent.
8,16 We also note that the FdL assay uses trypsin and
compounds that inhibit this protease, but not the KDAC, would
represent false-positive hits. We therefore tested whether the six
unconﬁrmedhitsinhibittrypsinactivityusingadeacetylatedFdL
substrate, and we found that they did not, suggesting that the six
compounds arefalse-positive hits thatmayresult from anartifact
of the ﬂuorescent assay.
To compare the robustness of the SAMDI and FdL assays, we
calculated the Z0-factor, which measures the ability of an assay
to distinguish positive signals from background.
17 A value of 1.0
represents an ideal assay, though values greater than 0.7 are
well-suited for high-throughput screening applications. For our
Figure 3. Comparison of SAMDI and Fluor de Lys assays as high-
throughput screening tools. (a) Table of the details of each screen. (b)
Z0-factor calculation of the SAMDI assay across the screen. (CV =
coeﬃcient of variation for the positive control, where CV = standard
deviation/mean). (c) Z0-factor calculation for Fluor de Lys assay across
one 96-well plate.
Figure 2. Combination of SAMDI-MS and peptide arrays gives a high-
throughput screening method. (a) Image of a stainless steel array plate
havinganarrayofgoldfeaturesinthegeometryofa384-microtiterplate.
(b) Representative series of SAMDI spectra from the screen where the
black spectra indicate deacetylated substrates and the red spectrum
indicates the parent peptide, and therefore an initial hit. (c) Inhibition
curve for our lead compound having an IC50 value of 200 nM.350 dx.doi.org/10.1021/co2000373 |ACS Comb. Sci. 2011, 13, 347–350
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comparison, we ran one 384-well plate for SAMDI and one
manufacturer provided 96-well plate for FdL, where half of the
wells contained 1 μM KDAC8 (positive controls) and the
remaining half were without enzyme (negative controls).
We determined the mean and standard deviation for each assay
and used them to calculate the Z0-factor. For SAMDI, we
obtained a Z0-factor of 0.95, whereas we obtained a Z0-factor of
0.75 for FdL (Figure 3c). While the FdL Z0-factor value is
acceptable as a high-throughput assay, SAMDI clearly shows a
superior Z0-factor and, therefore, has much less potential for
false-positive signals, as observed above. We also calculated the
Z0-factoracrosstheentireSAMDIscreenandobtainedavalueof
0.84 (Figure 3b).
The SAMDI method also represents an advance over other
important MS methods developed for screening applications.
Thedesorption/ionizationonsilicon(DIOS) method,forexample,
has the primary beneﬁt that it does not require matrix and can
therefore analyze small molecules. Most applications of the DIOS
method have not used covalent capture of the analyte and
therefore can require more complex protocols for sample pre-
paration. However, Finn, Siuzdak, and co-workers have reported
a related approach that employs cleavable linkers and may oﬀer
another route to high-throughput applications.
18,19 Additionally,
the RapidFire method allows high-throughput analysis using
mass spectrometry but requires a solid phase extraction or
chromatographic sample preparation of the analyte before mass
analysis.
4WithSAMDI,thearrayplates(384spots)needonlybe
rinsed and treated with matrix after analyte immobilization.
This paper describes the use of SAMDI for high-throughput
inhibitor screening. By translating the assay to 384-spot array
plates and by accessing laboratory automation equipment and
protocols, we show that the assay can screen a 100000 molecule
library in one day, making this method competitive with many
mature technologies used in HTS.
’ASSOCIATED CONTENT
b S Supporting Information. Detailed experimental meth-
ods and supplemental ﬁgures describing inhibitor ranking and
assay comparison. This material is available free of charge via the
Internet at http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*E-mail: mmrksich@uchicago.edu. Fax: 773-702-1677.
Funding Sources
This work was supported by the NIH (RO1 GM084188, P50
GM086145, and U54 CA151880).
’REFERENCES
(1) Mayr, L. M.; Bojanic, D. Novel trends in high-throughput
screening. Curr. Opin. Pharmacol. 2009, 9, 580–588.
(2) Chakraborty, C.; Hsu, C. H.; Wen, Z. H.; Lin, C. S. Recent
advances of ﬂuorescent technologies for drug discovery and develop-
ment. Curr. Pharm. Des. 2009, 15, 3552–3570.
(3) Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; West-
man, E. A.; Caldwell, S. D.; Napper, A.; Curtis, R.; DiStefano, P. S.;
Fields, S.; Bedalov, A.; Kennedy, B. K. Substrate-speciﬁc activation of
sirtuins by resveratrol. J. Biol. Chem. 2005, 280, 17038–17045.
(4) Shiau, A. K.; Massari, M. E.; Ozbal, C. C. Back to basics: Label-
free technologies for small molecule screening. Comb. Chem. High
Throughput Screening 2008, 11, 231–237.
(5) Greis, K. D. Mass spectrometry for enzyme assays and inhibitor
screening: an emerging application in pharmaceutical research. Mass
Spectrom. Rev. 2007, 26, 324–339.
(6) Mrksich,M.Massspectrometryofself-assembledmonolayers:A
new tool for molecular surface science. ACS Nano 2008, 2,7 –18.
(7) Gurard-Levin, Z. A.; Mrksich, M. Combining self-assembled
monolayers and mass spectrometry for applications in biochips. Annu.
Rev. Anal. Chem. 2008, 1, 767–800.
(8) Gurard-Levin, Z. A.; Kim, J.; Mrksich, M. Combining mass
spectrometry and peptide arrays to proﬁle the speciﬁcities of histone
deacetylases. ChemBioChem 2009, 10, 2159–2161.
(9) Kim,J.;Mrksich, M.Proﬁlingtheselectivity ofDNAlinases with
mass spectrometry. Nucleic Acids Res. 2009, 38,1 –10.
(10) Min, D. H.; Tang, W. J.; Mrksich, M. Chemical screening by
mass spectrometry to identify inhibitors of anthrax lethal factor. Nat.
Biotechnol. 2004, 22, 717–723.
(11) Houseman, B. T.; Gawalt, E. S.; Mrksich, M. Maleimide-
functionalized self-assembled monolayers for the preparation of peptide
and carbohydrate biochips. Langmuir 2003, 19, 1522–1531.
(12) Mingalyov, P. G.; Lisichkin, G. V. Chemical modiﬁcation of
oxide surfaces with organophosphorus(V) acids and their esters. Russ.
Chem. Rev. 2006, 75, 541–557.
(13) Gawalt, A. S.; Avaltroni, M. J.; Koch, N.; Schwartz, J. Self-
assembly and bonding of alkanephosphonic acids on the native oxide
surface of titanium. Langmuir 2001, 17, 5736–5738.
(14) Haberland, M.; Montgomery, R. L.; Olson, E. N. The many
roles of histone deacetylases in development and physiology; implica-
tions for disease and therapy. Nat. Rev. Genet. 2009, 10,3 2 –42.
(15) Wegener, D.; Hildmann, C.; Riester, D.; Schober, A.; Meyer-
Almes, F. J.; Deubzer, H. E.; Oehme, I.; Witt, O.; Lang, S.; Jaensch, M.;
Makarov, V.; Lange, C.; Busse, B.; Schwienhorst, A. Identiﬁcation of
novel small-molecule histone deacetylase inhibitors by medium-
throughput screening using a ﬂuorigenic assay. Biochem. J. 2008,
413, 143–150.
(16) Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.;
Flynn,D.;Garofalo,R.S.;Griﬃth,D.;Griﬀor,M.;Loulakis,P.;Pabst,B.;
Qiu,X.Y.;Stockman,B.;Thanabal,V.;Varghese,A.;Ward,J.;Withka,J.;
Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct
activators of SIRT1. J. Biol. Chem. 2010, 285, 8340–8351.
(17) Zhang,J.H.;Chung,T.D.;Oldenburg,K.R.Asimplestatistical
parameter for use in evaluation and validation of high throughput
screening assays. J. Biomol. Screen. 1999, 4,6 7 –73.
(18) Shen,Z.;Go,E.P.;Gamez,A.;Apon,J.V.;Fokin,V.;Grieg,M.;
Ventura, M.;Crowell,J.E.;Blixt,O.; Paulson, J.C.;Stevens,R.C.;Finn,
M. G.; Siuzdak, G. A mass spectrometry plate reader: Monitoring
enzyme activity and inhibition with a desorption/ionization on silicon
(DIOS) platform. ChemBioChem 2004, 5, 921–927.
(19) Meng,J.C.;Averbuj,C.;Lewis,W.G.;Siuzdak, G.;Finn,M.G.
Cleavable linkers for porous silicon-based mass spectrometry. Angew.
Chem., Int. Ed. 2004, 43, 1255–1260.